Nirvana Life Sciences Inc · CSE:NIRV.X
Nirvana Life Sciences — Investor Presentation (March 2022)
24 slides from Nirvana Life Sciences's investor presentation, March 2022
Slide 1: Focused on developing medical products and regimens that address addiction
Focused on developing medical products and regimens that address addiction.
Slide 2: Our Mission
Our Mission • Nirvana was founded with the intent to develop novel therapeutic products derived from psychedelics. • There is a growing body of research that leads to the conclusion that psychedelic based medicines can offer new approaches to pain management as well as treatment for ailments such ad
Slide 3: Opioids Addiction has become a global crisis
Opioids Addiction has become a global crisis • For many years, the pharmaceutical Industry has promoted the use of highly addictive pain medications to millions of patients. While these medications have been effective for pain relief, the highly addictive nature of the medications has created a prob
Slide 4: Four Pillars of Success
Four Pillars of Success Research & Development of IP Acquired the IP behind these novel formulations Advancing research on a number of these formulations Advancing research on 4-PO tryptamine analog Development of Processes to support production Acquired a license for the extraction technology Devel
Slide 5: Breakthrough Research
Breakthrough Research • The Company’s Scientific team is taking theories developed by researchers in the 60’s and 70’s and applying modern approaches to developing novel psychedelics-based medicines. • Company researchers believe that its novel Psilocibyn formulation may also be effective at prevent
Slide 6: Therapeutic Products
Therapeutic Products The Company has identified two target two products for its first phase of development: First, a one-per-day slow release gel cap that assists transition from opioids to non-addictive pain relief therapies by preventing relapse. Second, a one-per-day slow release gel cap that del
Slide 7: Novel Formulations
Novel Formulations • The company has purchased a portfolio of Intellectual Property from researchers with vast experience in the psychedelics space. • Nirvana’s researchers have developed formulations based on psychedelics for aiding patients who are addicted to opioids to transition off these subst
Slide 8: Extraction of Natural materials
Extraction of Natural materials • Nirvana has prioritized extraction of natural materials to create therapeutic compounds while others have focused on synthetic materials. • The Company’s extraction process development includes large scale extraction, isolation and purification of psilocybin and oth
Slide 9: Extraction- Synthetic
Extraction- Synthetic • The International Centre for Genetic Engineering and Biotechnology of New Delhi, India has been contracted to undertake a research project on a novel process developed by the Company’s CSO to assess a process to produce psilocybin materials at scale. • The project is focussin
Slide 10: PureAI Distillation System
PureAI Distillation System • Nirvana has acquired an exclusive license to the extraction and distillation technology for the Psychedelics market. The Company has purchased its first PureAI machine that will be in the Vancouver Lab facility. • The Pure AI is a high vacuum fractional distillation syst
Slide 11: Research Facility
Research Facility • The company has secured a location in Vancouver to conduct research that is suitable for this development. • The company has received a Section 56 Exemption (research license) from Health Canada. • The team has extensive experience planning and building similar facilities. • The
Slide 12: Pre-Clinical Trails
Pre-Clinical Trails • The Company began a series of pre-clinical trials in the spring of 2021 Clinical Studies are led by Dr. Massimo Nabissi of the University of Camerino (Italy) with the support of Dr. Sazzad Hossain. • Dr. Nabissi’s lab was granted special permission from the Italian government t
Slide 13: Connie Hang, CPA
Connie Hang, CPA Chief Financial Officer • Ms. Hang has over 20 years of finance, accounting, and management experience in a variety of industries, including energy, mining, and health science. • In the past 12 years Ms. Hang has acted as an advisor, officer and/or director for various public and pr
Slide 14: Dr. Sazzad Hossain PhD
Dr. Sazzad Hossain PhD Chief Scientific Officer • Dr. Hossain is the former Chief Scientific Officer of InMed Pharmaceuticals Inc., a leading public Canadian bio-pharmaceutical company. • Previously he worked as Senior Scientist at Biotechnology Research Institute of National Research Council Canada
Slide 15: Andrew Samann, MSc
Andrew Samann, MSc Chief Compliance Officer • Andrew is the founder of Orion GMP Solutions , a pharmaceutical consulting firm that brings expertise in Pharmaceutical Quality Management Systems (QMS) and Good Manufacturing Practices (GMP) to the international cannabis industry. • Andrew’s experience
Slide 16: Robert August IV, MSc
Robert August IV, MSc Head of Innovation • Robert is an academically trained medicinal chemist with a focus on ergolines, phenethylamines and tryptamines. • Robert began his academic career at Loyola University in Baltimore, Maryland. During his undergraduate years, Robert worked as an analytical ch
Slide 17: Michael McCune
Michael McCune Vice President Operations • Mr. McCune is a seasoned entrepreneur and innovator in the extraction space. • Since 2013, he has applied his passion for science to developing novel processes for producing API's for Cannabis industry. He has built a specialty for at-scale extraction of a
Slide 18: Dr. Massimo Nabissi, PhD
Dr. Massimo Nabissi, PhD Head of Clinical Trials • Dr Massimo Nabissi is a Professor in the Scientific sector at the University of Camerino, Italy. His principal area of research are in molecular and cellular biology focused on human cancers: glioblastoma, multiple myeloma, bladder, prostate and pan
Slide 19: Dr Naseem Gaur, PhD
Dr Naseem Gaur, PhD Head of Biosynthetic Research. • Dr. Gaur is the group leader of Integrative Biology-Yeast and Biofuels, at the International Centre for Genetic Engineering and Biotechnology, New Delhi, India. • Current research interest focuses on developing yeast strains for bio-based chemical
Slide 20: Sheldon Inwentash, B.Comm., CA., CPA., LL.D.
Sheldon Inwentash, B.Comm., CA., CPA., LL.D. Chair of Advisory Board • Mr. Inwentash is the Founder, Chairman and CEO of ThreeD Capital Inc. • Mr. Inwentash has more than 30 years of investing experience. He co-founded Visible Genetics, the first commercial pharmacogenomics company, in 1994 and exit
Slide 21: Jakson Inwentash, CFA
Jakson Inwentash, CFA Advisory Board Member • Mr. Inwentash is a director and VP Investments at ThreeD, where he focuses on identifying, researching, and meeting with early stage companies in various disruptive industries to invest into. • Previously, he worked in investment banking for Gravitas Sec
Slide 22: Use of Proceeds
Use of Proceeds • Research 1,400,000 • Product Development 1,100,000 • Pre-Clinical and Clinical Trials 1,600,000 • GMP Facility and Equipment 2,500,000 • Working Capital 3,400,000 • Total 10,000,000
Slide 23: Capitalization Table
Capitalization Table POST RTO CAP TABLE Shares subject to Date Price per Share Amount Raised Shares Issued Escrow Nirvana Life Sciences Inc. Founders $ 0.001 $ 10,923.00 10,923,000 14,173,000 Builders $ 0.02 $ 93,000.00 4,650,000 Private Placement Dec-20 $0.15 $800,000.00 5,333,333 Private Placement
Slide 24: Contact
Contact Nirvana Life Sciences Inc. email: investor@nirvanalifescience.com tel : (604) 401-8100 www.nirvanalifescience.com 2110- 650 West Georgia Street Vancouver, BC
Nirvana Life Sciences — Investor Presentation (March 2022) on 6ix